Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00179673 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkins Lymphoma

Interventions

DRUG: Lenalidomide

Sponsor

Celgene

Collaborators

[object Object]